Drug Profile


Alternative Names: AZD 6474; Caprelsa; Zactima; ZD 6474; Zictifa

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Hoosier Cancer Research Network; Sanofi; University of Oxford
  • Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Phase II Malignant melanoma; Small cell lung cancer
  • No development reported Brain metastases
  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 20 Sep 2016 No development reported - Phase-I for Brain metastases in Netherlands (PO)
  • 26 Aug 2016 Sanofi terminates a phase I trial in Brain metastases in the Netherlands (NCT00807170)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top